Scinovex
review Open AccessTop 1% cited

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes Care · 2022 · Vol. 45(11) · pp. 2753–2786
Melanie J. DaviesVanita R. ArodaBilly S. CollinsRobert A. GabbayJennifer GreenNisa M. MaruthurSylvia E. RosasStefano Del PratoChantal MathieuGeltrude MingronePeter RossingTsvetalina TankovaΑπόστολος ΤσάπαςJohn B. Buse

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

Diabetes Treatment and ManagementDiabetes Management and ResearchDiet and metabolism studiesMedicineDiabetes mellitusType 2 diabetesInternal medicineEndocrinologyAssociation (psychology)

MeSH terms

Glucagon-Like Peptide-1 ReceptorAdultDiabetes Mellitus, Type 2EuropeHumansHyperglycemiaHypoglycemic AgentsUnited StatesConsensus

Funding

  • American Diabetes Association
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Gilead Sciences
  • Ohio State University
  • Medpace
  • Johns Hopkins University
  • University Hospitals of Leicester NHS Trust
  • Insulet Corporation
  • ReCor Medical
  • Dexcom
  • Moderna
  • University of Leicester
  • University of Southampton
  • Newcastle University
  • KU Leuven
  • Novo Nordisk
  • Sapienza Università di Roma
  • Astellas Pharma
  • Universitat de Barcelona
  • Aristotle University of Thessaloniki
  • European Association for the Study of Diabetes
  • Servier
  • University of North Carolina at Chapel Hill
  • Takeda Pharmaceuticals International
Citations
1,800
FWCI
221.40
field-weighted impact
References
354
Percentile
100%
vs. same field & year
Citations per year
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.